Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICKI: Venetoclax + T-DM1 in HER2+ Breast Cancer
NCT04298918Phase 2Terminated
- Sponsor
- Roche
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax in HER2-positive breast cancer, sponsored by Roche. Started Sep 2020; status: terminated.
02
Drugs
venetoclax
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04298918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298918.